Literature DB >> 6124437

Pharmacological properties of diacetolol (M & B 16,942), a major metabolite of acebutolol.

B Basil, R Jordan.   

Abstract

Diacetolol (M & B 16,942), the major metabolite of the beta-adrenoceptor blocking agent, has been compared pharmacologically with acebutolol. In vitro, the beta-adrenoceptor blocking potency of diacetolol was less than that of acebutolol but its cardioselectivity (atrial relative to tracheal tissue) was greater. In the anaesthetized cat both agents had closely similar beta-adrenoceptor blocking potency and cardioselectivity. Diacetolol had weak intrinsic sympathomimetic activity (ISA), and no significant membrane-stabilizing activity (MSA). It did not restore sinus rhythm to anaesthetized dogs with ouabain-induced arrhythmias but was similar to acebutolol in preventing arrhythmia induced by adrenaline/methylchloroform in anaesthetized cats. It is concluded that, in experimental animals, diacetolol has beta-adrenoceptor blocking properties and ISA similar to the parent compound but differs in its lack of MSA.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124437     DOI: 10.1016/0014-2999(82)90176-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  New drugs: beta blockers and sympathomimetics.

Authors:  C M Kaye
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-30

2.  New drugs: beta blockers and sympathomimetics.

Authors:  J Feely; D Maclean
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-18

Review 3.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

4.  Comparison of beta-adrenoceptor selectivity of acebutolol and its metabolite diacetolol with metoprolol and propranolol in normal man.

Authors:  M S Thomas; A E Tattersfield
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.